Core Viewpoint - The growth myth of Aimeike (300896.SZ), known as the "beauty medical king," is collapsing as the company faces significant revenue and profit declines amid intensified competition in the medical aesthetics industry [1][2][3]. Financial Performance - In the first half of this year, Aimeike's revenue dropped by 21.59% to 1.299 billion yuan, and net profit attributable to shareholders fell by 29.57% to 789 million yuan, marking the first time the company experienced a dual decline in mid-year performance since its listing [3][4]. - The second quarter saw a dramatic decline in net profit, plummeting by 41.75% to 346 million yuan, with revenue down 25.11% to 636 million yuan [3][4]. - Aimeike's cash flow from operating activities also showed a warning sign, decreasing by 43.06% from 1.15 billion yuan in the same period last year to 655 million yuan [3]. Market Competition - The medical aesthetics industry is entering a fully competitive phase, with numerous new entrants, including Huaxi Biological, which has disrupted Aimeike's monopoly on its flagship product "Haitai" [1][5]. - The core product "Haitai," which was once the market leader, is now facing declining sales and market share due to increased competition and the introduction of new products [5][6]. Product Performance - Aimeike's solution injection products generated revenue of 744 million yuan in the first half of the year, a decline of 23.79% year-on-year, primarily due to intensified industry competition [4][6]. - The revenue from gel injection products, represented by "Ruhua Tianzi," also showed signs of slowing growth, with a 23.99% decline in the first half of the year [6]. Strategic Moves - To overcome growth bottlenecks, Aimeike invested heavily in acquiring the Korean company REGEN, aiming to enter the "youthful needle" market [1][7]. - However, the acquisition has led to a significant arbitration dispute over agency rights, with potential financial implications of up to 1.6 billion yuan [8][9]. Industry Outlook - According to a report, the Chinese medical aesthetics industry is expected to experience continuous market growth but with a slowdown in growth rates, indicating a strategic transition from scale expansion to value reconstruction [5].

Core Insights - Aimeike reported its first half-year results since listing, showing declines in both revenue and net profit, with revenue at 1.299 billion yuan, down 21.59% year-on-year, and net profit at 789 million yuan, down 29.57% [1][3] - The company attributes these fluctuations to adjustments in the medical aesthetics industry and consumer environment, viewing it as a normal phase in industry development [3] Revenue and Profit Decline - Aimeike's revenue and net profit have been on a downward trend, with a significant drop in the first half of 2025 compared to previous periods [3][4] - The two core business segments, solution-based and gel-based injection products, experienced revenue declines of 23.79% and 23.99%, respectively [1][3] Product Competition and Market Challenges - The core products "Haitai" and "Ruhbai Tianqi" face increasing competition, with new entrants in the market eroding Aimeike's previous dominance [4][5] - The competitive landscape has intensified, leading to price wars and necessitating continuous innovation and quality improvement from Aimeike to maintain market position [5] R&D and Acquisition Strategy - To counteract the challenges in core product growth, Aimeike is increasing R&D investment, which reached 157 million yuan in the first half of 2025, a 24.47% increase year-on-year [6] - The company acquired 85% of South Korean REGEN for approximately 1.9 billion USD, aiming to expand its product line and leverage REGEN's overseas sales channels [7] Legal and Operational Risks - Aimeike faces potential legal disputes over distribution rights for REGEN's products, which could impact its market performance and strategic goals [8][9] - The ongoing arbitration regarding distribution rights with Jiangsu Wuzhong could lead to significant financial implications, with claims amounting to 1.6 billion yuan [8][9]

Core Viewpoint - Aimeike faces significant performance challenges, with a sharp decline in revenue and net profit in the first half of 2025, marking the most severe performance challenge since its listing [2][3]. Financial Performance - Aimeike reported a revenue of 1.299 billion yuan, a year-on-year decrease of 21.59% [3][4]. - The net profit attributable to shareholders was 789 million yuan, down 29.57% year-on-year [3][4]. - Basic earnings per share decreased to 2.62 yuan, a reduction of 29.57% [3][4]. - Operating cash flow net amount was 655 million yuan, down 43.06% year-on-year [3][4]. - The weighted average return on equity fell to 10.10%, a decrease of 6.52 percentage points [4]. Product Performance - Core products, including the solution-type product "Haitai" and gel-type product "Ruhbai Tianzi," experienced significant revenue declines, with solution-type products generating 744 million yuan (down 23.79%) and gel-type products generating 493 million yuan (down 23.99%) [7][8]. - The gross margin for solution-type products was 93.15%, while for gel-type products it was 97.75% [8]. Market Dynamics - Aimeike attributes the poor performance of its core products to intensified competition and market transformation within the medical aesthetics industry [9][10]. - The report highlights a growing divide between high-end and mass markets, with new materials for injection products becoming industry focal points [9][10]. Strategic Moves - Aimeike announced a dividend plan, proposing a cash dividend of 12 yuan per 10 shares, totaling approximately 362 million yuan, which accounts for 45.9% of net profit [5]. - The company acquired 85% of South Korea's REGEN for 1.9 billion USD, gaining production rights for "Tongyan Needle," aiming to alleviate capacity bottlenecks and enhance its product matrix [12][13]. - Aimeike is expanding its product line to include weight loss products, with clinical trials for Semaglutide and Deoxycholic Acid injections underway [13][14].

Core Viewpoint - The dispute over the exclusive agency rights for the "童颜针" (AestheFill) between *ST Suwu and the medical beauty giant Aimeike has escalated, with *ST Suwu seeking arbitration and claiming significant financial losses due to alleged breaches of contract [2][5][6]. Group 1: Company Actions and Legal Proceedings - *ST Suwu's subsidiary, Datou Medical, has filed for arbitration with the Shenzhen International Arbitration Court regarding a breach of contract by Regen, seeking to confirm its exclusive agency rights for AestheFill and claiming preliminary damages of 1.6 billion yuan [2][6]. - The arbitration request was accepted by the Shenzhen International Arbitration Court on August 7, 2025 [5]. - *ST Suwu has publicly accused Aimeike of "capital bullying" and "serious damage to business ethics" in its defense [2][8]. Group 2: Financial Context and Company Performance - *ST Suwu is facing severe financial difficulties, including risks of forced delisting due to financial fraud allegations, with a reported inflated revenue of 1.77 billion yuan from 2020 to 2023 [3][9]. - Aimeike, which acquired 85% of Regen for $190 million in March 2025, is also experiencing declining financial performance, with revenue and net profit growth rates dropping to single digits in 2024 [3][12]. - Aimeike's market capitalization has decreased from over 180 billion yuan at its peak to approximately 60 billion yuan, reflecting a loss of over 120 billion yuan [4][14]. Group 3: Market Implications and Future Outlook - The ongoing dispute over the AestheFill agency rights is critical for both companies, as AestheFill is seen as a potential growth driver for Aimeike amidst its declining performance [10][11]. - The market has reacted negatively to the news, with *ST Suwu's stock price experiencing consecutive trading halts following the announcement of the termination of its agency rights [8]. - The outcome of the arbitration and the future of the AestheFill product in the Chinese market remain uncertain, with significant implications for both companies and their stakeholders [4][15].

Core Viewpoint - The recent allegations of financial fraud against Huaxi Biological have led to a significant decline in its stock price and raised concerns about its internal governance and market position [2][3][4]. Company Overview - Huaxi Biological's stock price closed at 52.43 yuan per share, down 2.6%, with a total market capitalization of 25.254 billion yuan as of July 28 [2]. - The company's stock has been in a downward trend since reaching a peak of 314.99 yuan per share in July 2021, hovering around 50 yuan per share this year [2]. Allegations and Responses - A former employee, David Li, accused Huaxi Biological of serious financial fraud and bond issuance fraud in a social media post, which has stirred controversy in the medical aesthetics industry [2][3]. - Huaxi Biological issued a statement denying the allegations, claiming they are fabricated and maliciously distorted, and reported Li to the police for defamation [3]. Internal Governance Issues - This is not the first time Huaxi Biological has faced internal allegations; previous reports included claims of coercion and financial misconduct involving the company's chairman [6][7]. - The company has acknowledged past governance issues and is undergoing significant internal reforms, including restructuring and talent management changes [7][8]. Financial Performance - In 2024, Huaxi Biological reported a revenue of 5.371 billion yuan, a year-on-year decline of 11.61%, and a net profit of 174 million yuan, down 70.59% [9][10]. - The decline in revenue is largely attributed to a significant drop in the skin science innovation business, which saw a 31.62% decrease in revenue [10]. Market Environment - The medical aesthetics market is experiencing a shift from hyaluronic acid to collagen and regenerative products, posing additional challenges for Huaxi Biological [11]. - The company is facing intense competition and has established a "competitive intelligence department" to monitor and respond to market dynamics [8][9].

Core Insights - The medical beauty sector is becoming a strategic focus for major companies, driven by the need for medical professionalism, commercial sustainability, and social responsibility [1][3] - JD.com has entered the medical beauty market with its first self-operated clinic opening in Beijing, indicating a competitive landscape with other giants like Alibaba, Meituan, Douyin, and Tencent already involved [2][4] - The competition is centered around high-value users and high-profit scenarios, making differentiation crucial for success [3] JD.com's Strategy - JD.com has adopted a direct approach by opening self-operated clinics and has partnered with New Oxygen, a leading internet medical beauty platform, to enhance its service offerings [5][6] - The company has established direct supply chain collaborations with top manufacturers, creating a short-chain model that reduces costs by eliminating intermediaries [7] Comparison with Competitors - Meituan, while entering the market earlier, has focused on a consulting and intermediary role rather than direct operation, leveraging its local service platform for traffic [8][9] - Alibaba's strategy mirrors Meituan's, acting as an intermediary while integrating medical beauty with its consumer finance services [9][10] - ByteDance has taken a more aggressive approach by acquiring medical institutions and launching its own medical beauty services, albeit entering the market later than others [10][12] Market Dynamics - The medical beauty industry is characterized by high profit margins, with midstream institutions enjoying gross margins of 40%-55% and downstream margins reaching 60%-80% [14] - The market is projected to grow significantly, with estimates suggesting it could reach 399.8 billion yuan by 2026 and 638.2 billion yuan by 2030, reflecting a compound annual growth rate of 12.4% [14] Challenges and Considerations - Major companies face structural challenges and competition for market share, with user engagement and budget constraints becoming critical issues [13][15] - The medical beauty sector is described as a "walled city," indicating intense competition and the need for companies to establish trust and credibility in a market where mistakes can have severe consequences [18][21] - Building a trust barrier through technology and compliance is essential for companies to succeed in the medical beauty space [21][22]

Core Viewpoint - The article discusses the significant decline in the wealth of Jian Jun, the leader of Aimeike, a prominent player in the medical beauty industry, highlighting the challenges faced by the company amid increasing competition and changing market dynamics [2][3]. Group 1: Wealth Decline of Jian Jun - Jian Jun's wealth has decreased from 525 billion yuan in 2023 to 220 billion yuan in 2025, a loss of 305 billion yuan over two years [2][3]. - Aimeike, under Jian Jun's leadership, has become a leading company in the medical beauty sector, forming a competitive landscape with Huaxi Biological and Haohai Biological, known as the "three swordsmen of hyaluronic acid" [2][3]. - Despite previous high growth rates, Aimeike's revenue and net profit growth have slowed to single digits in 2024, with both metrics turning negative in Q1 2025 [2][10]. Group 2: Aimeike's Business Performance - Aimeike's revenue surged by 104.13% in 2021, reaching 1.448 billion yuan, with net profit increasing by 117.81% to 958 million yuan [10]. - In 2023, Aimeike's revenue reached 2.869 billion yuan, and net profit was 1.858 billion yuan, but growth rates fell to 5.45% and 5.33% respectively in 2024 [11]. - The company's gross margin has also declined, from 95.09% in 2023 to 93.85% in Q1 2025 [11]. Group 3: Strategic Moves and Acquisitions - In March 2025, Aimeike announced plans to acquire 85% of South Korean REGEN Biotech, Inc. for 1.9 billion USD, aiming to enhance its international presence and product offerings [12][13]. - The acquisition is seen as a strategic move to solidify Aimeike's leading position in the injectable product market and to drive future growth [13][14]. - Analysts believe that this overseas acquisition could provide new growth opportunities for Aimeike amid a challenging domestic market [12][13].

谢您的关注。 4、请问 25 年各大股东还有减持计划吗？ 答：尊敬的投资者您好，公司目前未收到相关股东减持计划的通知。 感谢您的关注。 5、你好，面对业绩增速下滑，公司有没有应对措施？后续有没有计 划在电商平台销售产品？ 答：尊敬的投资者您好，随着公司经营体量基数加大，增速有一定 程度下降，公司从 2025 年开始，研发完成交付上市的产品会渐次投放市 场，形成对公司发展和业绩的支撑；公司主销产品为三类植入医疗器械， 不能在普通的无三类医疗器械经营资质的电商平台开展销售服务。感谢 关注。 爱美客技术发展股份有限公司 投资者关系活动记录表 编号：2025-001 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ☑业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 通过全景网"投资者关系互动平台"(http://ir.p5w.net)参与 2024 年 | | 人员姓名 | 度网上业绩说明会的投资者 | | 时间 2025 | 年 3 月 21 日 15: ...